(vianews) - guerbet (gbt.pa) is among this list of stock assets with the highest dividend rate and return on equity on the healthcare sector.
| financial asset | price | forward dividend yield | return on equity |
|---|---|---|---|
| guerbet (gbt.pa) | €32.85 | 1.35% | 5.85% |
| vetoquinol (veto.pa) | €99.50 | 0.81% | 10.98% |
several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.
1. guerbet (gbt.pa)
1.35% forward dividend yield and 5.85% return on equity
guerbet sa engages in the development and marketing of contrast media products, delivery systems, medical devices, and related solutions. the company offers optiray and xenetix, which are non-ionic monomeric and iodinated contrast agents; telebrix gastro, a meglumine ioxitalamate solution; conray, an iothalamate meglumine injection; micropaque/microtrast, a diagnostic imaging interconnected solution; dotarem, a gadoteric acid-gadoterate meglumine, and artirem, a gadoteric acid that acts as a contrast agent for mri, as well as prefilled syringes, injectors, accessories, and consumables for mri, ct, and cath lab. it also provides digital solutions, such as contrast&care, an injection management solution; dose&care, an x-ray dose management solution; and icobrain, a cloud-based ai solution to quantify disease-specific brain structures for acute and chronic neurological conditions on mr and ct, as well as optiprotect services. in addition, the company provides products for interventional radiology, including lipiodol ethyl esters of iodinated fatty acids of poppyseed oil; vectorio, a mixing and injection system for conventional trans-arterial chemoembolization; patent blue v, a blue dye; axessio, a peripheral micro guidewire; and sequre and drakon, which are microcatheters. further, it offers hydra vision, a digital imaging system for urological, gastroenterological, and gynecological treatment, as well as planning and diagnostic procedures; and urology accessories and consumables. guerbet sa was incorporated in 1926 and is headquartered in villepinte, france.
earnings per share
as for profitability, guerbet has a trailing twelve months eps of €-3.35.
return on equity
the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 5.85%.
volume
today's last reported volume for guerbet is 14593 which is 41.9% below its average volume of 25120.
stock price classification
according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, guerbet's stock is considered to be overbought (>=80).
moving average
guerbet's worth is under its 50-day moving average of €34.98 and way higher than its 200-day moving average of €24.28.yearly top and bottom value
guerbet's stock is valued at €32.85 at 07:30 est, way under its 52-week high of €38.75 and way above its 52-week low of €15.48.
more news about guerbet.
2. vetoquinol (veto.pa)
0.81% forward dividend yield and 10.98% return on equity
vetoquinol sa, a veterinary pharmaceutical company, designs, develops, and sells veterinary drugs and non-medicinal products in europe, the americas, and the asia pacific region. it provides products in the areas of mobility, pain, and inflammation; dermatology, hygiene, and care; anti-parasite; udder health; infectious diseases; reproduction; behavior management; internal medicine; and cardiology-nephrology for cattle, sheep, pigs, poultry, dogs, cats, and horses. the company was founded in 1933 and is headquartered in lure, france. vetoquinol sa is a subsidiary of soparfin sca.
earnings per share
as for profitability, vetoquinol has a trailing twelve months eps of €4.97.
pe ratio
vetoquinol has a trailing twelve months price to earnings ratio of 20.02. meaning, the purchaser of the share is investing €20.02 for every euro of annual earnings.
return on equity
the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 10.98%.
revenue growth
year-on-year quarterly revenue growth grew by 1.5%, now sitting on 529.27m for the twelve trailing months.
volume
today's last reported volume for vetoquinol is 4463 which is 47.48% above its average volume of 3026.
yearly top and bottom value
vetoquinol's stock is valued at €99.50 at 07:30 est, under its 52-week high of €110.00 and way higher than its 52-week low of €76.30.
more news about vetoquinol.